A £14 million ($18 million) investment from Cancer Research UK will go towards the establishment of a new research center for biopharmaceuticals, based in London.
The new Cancer Research UK City of London Centre will act as a hub for researchers from leading research centers, including University College London (UCL), King’s College London, Queen Mary University of London and the Francis Crick Institute.
Research will span all cancer types, with a focus on childhood cancers. The center will be driven by an ethos of collaboration and training.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze